Nanobiotix S.A. NBTX
30.63 USD +0.61 (+2.03%)
At closeNov 6, 2026, 4:00 PM EST
30.63 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
29.16 Day range 30.83
19.67 52-week range 55.07
- YTD
- +32.48%
- 1 year
- +55.72%
- Market cap
- 1.56B
- Revenue (ttm)
- 11.51M
- EPS (ttm)
- -1.27
- Shares out
- 50.95M
- Forward P/E
- -182.62
- YTD return
- +32.48%
- 1-year return
- +55.72%
- Volume
- 136.24K
- Avg volume
- 159.07K
- Open
- 29.16
- Previous close
- 30.02
- Day's range
- 29.16 – 30.83
- 52-week range
- 19.67 – 55.07
- Beta
- 0.54
- Analysts
- Strong Buy
- Price target
- 54.14 (+76.7%)
- Earnings date
- Apr 27, 2027
5D +1.05 (+3.57%)
Key statistics
- Enterprise value
- 1.52B
- PEG ratio
- 0.00
- Price / sales
- 135.62
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -79.20%
- Free cash flow
- -32.78M
- Total cash
- 110.89M
- Total debt
- 106.61M
- Return on equity
- 0.00%
- Short % of float
- 0.52%
- 50-day average
- 31.47
- 200-day average
- 34.01
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 54.14 +76.7% upside
Now 30.63
- Target (low)
- 30.01
- Target (mean)
- 54.14
- Target (high)
- 69.66
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy0
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Apr 27, 2027
Expected Apr 27, 2027. Consensus EPS estimate 0.00.
Financials — quick view
NBTX Revenue — annual 32.59M
NBTX Net income — annual -23.96M
NBTX EPS — annual -0.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 27, 2027 | Dec 30, 2026 | 0.05703 | — | — | — |
| Sep 29, 2026 | Jun 30, 2026 | -0.48457 | -0.7981 | -0.31 | -64.70% |
| Mar 31, 2026 | Dec 31, 2025 | 0.3039 | -0.45809 | -0.76 | -250.74% |
| Sep 30, 2025 | Jun 30, 2025 | -0.24704 | -0.13367 | +0.11 | +45.89% |
| Apr 2, 2025 | Dec 31, 2024 | -0.62 | -1.01 | -0.39 | -63.46% |
| Nov 12, 2024 | Jun 30, 2024 | -0.5117 | -0.49906 | +0.01 | +2.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | main | Outperform | Outperform |
| May 1, 2026 | UBS | main | Neutral | Neutral |
| Apr 2, 2026 | Guggenheim | main | Buy | Buy |
| Feb 6, 2026 | Guggenheim | main | Buy | Buy |
| Apr 4, 2025 | Guggenheim | main | Buy | Buy |
| Aug 28, 2024 | Guggenheim | init | — | Buy |
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- nanobiotix.com
News
Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session 
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday 
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday 
Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY 
Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64 
Nanobiotix Says JNJ-1900 (NBTXR3) Shows 61% One-Year Local Progression-Free Survival And 70% One-Year Overall Survival In Phase 1 NSCLC Trial 
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday 
12 Health Care Stocks Moving In Monday's Intraday Session 
Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46 
Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026
Your note
Sign in to keep a note on NBTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 11.06% | 5,623,816 | 172.26M | Sep 29, 2026 |
| Morgan Stanley | 0.10% | 49,789 | 1.53M | Jun 29, 2026 |
| Jane Street Group, LLC | 0.06% | 32,180 | 985.67K | Jun 29, 2026 |
| HRT Financial LP | 0.05% | 27,332 | 837.18K | Jun 29, 2026 |
| Optiver Holding B.v. | 0.03% | 13,631 | 417.52K | Jun 29, 2026 |
| Xtx Topco Ltd | 0.03% | 15,855 | 485.64K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 4,489 | 137.50K | Sep 29, 2026 |
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.00% | 1,048 | 32.10K | Jul 30, 2026 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.00% | 1,649 | 50.51K | Aug 30, 2026 |